Holen Sie sich die Stockscreener-App
1.31
0.00%
0.00
Handel nachbörslich:
1.29
-0.02
-1.53%
Schlusskurs vom Vortag:
$1.31
Offen:
$1.26
24-Stunden-Volumen:
2.49M
Relative Volume:
1.32
Marktkapitalisierung:
$86.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.08M
KGV:
-0.6072
EPS:
-2.1574
Netto-Cashflow:
$-72.06M
1W Leistung:
-33.16%
1M Leistung:
-10.88%
6M Leistung:
+39.36%
1J Leistung:
-14.38%
1-Tages-Spanne:
$1.22
$1.37
1-Wochen-Bereich:
$0.9802
$2.0499
52-Wochen-Spanne:
$0.66
$2.4773
Io Biotech Inc Stock (IOBT) Company Profile
Firmenname
Io Biotech Inc
Sektor
Branche
Telefon
(457) 070-2980
Adresse
OLE MAALOES VEH 3, COPENHAGEN
Vergleichen Sie IOBT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
1.31 | 86.30M | 0 | -86.08M | -72.06M | -2.1574 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Io Biotech Inc Aktie (IOBT) Neueste Nachrichten
IO Biotech says cancer vaccine with Merck’s Keytruda outperformed in late-stage study - MSN
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛
IO Biotech sees potential despite cancer vaccine study failure. - AInvest
IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma - Seeking Alpha
IO Biotech - The Pharma Letter
IO Biotech Surges 32.9% on Mixed Trial Data: Can Clinical Promise Outpace Regulatory Doubts? - AInvest
IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal - Reuters
IO Biotech Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Does IO Biotech Inc. meet Warren Buffett’s criteriaFree Profit Target Calculator - thegnnews.com
IO Biotech, Inc.'s (NASDAQ:IOBT) Market Cap Dropped US$72m Last Week; Private Equity Firms Bore the Brunt - 富途牛牛
IO Biotech's Promising Phase 3 Results and FDA Engagement Bolster Buy Rating - AInvest
IO Bio plans cancer vaccine filing despite trial miss - pharmaphorum
IO Biotech's Cylembio Trial: Navigating Near-Miss Outcomes and FDA Pathways in Oncology Innovation - AInvest
IO Biotech's Near-Miss in Phase 3 Trial: A Case Study in Biotech Resilience and Strategic Value - AInvest
IO Biotech's Cylembio and KEYTRUDA Combo: A Near-Miss in Pivotal Trial—Is This a Buying Opportunity or a Cautionary Tale? - AInvest
IO Biotech Plans Cylembio Filing Despite ‘Narrowly Missed’ Phase III Endpoint - insights.citeline.com
IO Biotech stock price target lowered to $4 at Morgan Stanley By Investing.com - Investing.com South Africa
IO Biotech stock price target lowered to $4 at Morgan Stanley - Investing.com Canada
IO Biotech's Near-Miss in Cylembio Trial: A Lesson in Incremental Progress and Long-Term Value - AInvest
Skin tight: IO Biotech melanoma phase III misses ‘by a hair’ - BioWorld MedTech
IO Biotech (IOBT.O) Suffers Intraday Freefall: What’s Behind the 33.4% Drop? - AInvest
IO Biotech to pursue cancer vaccine approval despite Phase III miss - Yahoo Finance
IO Biotech's cancer vaccine shows improvement in late-stage study goal - MSN
Promising Phase 3 Results and Strategic FDA Engagement Bolster Buy Rating for IO Biotech - TipRanks
IO Biotech sees path forward for skin cancer vaccine despite study setback - BioPharma Dive
IO Biotech Plummets 23.7%: What’s Behind the Sharp Drop? - AInvest
IO Biotech Plummets 39% on Near-Miss in Key Trial, Hints at FDA Gambit - AInvest
IO Biotech to seek FDA filing even though cancer vaccine narrowly fails pivotal skin cancer study - Endpoints News
IO Biotech's cancer vaccine Cylembio falls short in Phase III melanoma trial - FirstWord Pharma
IO Biotech Shares Climb Following Encouraging Cancer Vaccine Trial Results - MSN
Mixed results for IO Biotech's cancer vaccine Cylembio - The Pharma Letter
IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x - Stocktwits
IO Biotech drops after cancer vaccine narrowly misses main goal of late-stage study - TradingView
IO Biotech's Phase 3 Trial Fails To Deliver (NASDAQ:IOBT) - Seeking Alpha
IO Biotech's Skin Cancer Vaccine Combo Falls Short of Expectations, Seeks FDA Approval - AInvest
IO Biotech’s cancer vaccine shows improvement, but narrowly misses study goal - The Mighty 790 KFGO
Why Is IO Biotech Stock Falling Monday?IO Biotech (NASDAQ:IOBT) - Benzinga
IO Biotech’s cancer jab falls short in Phase 3, but Danish firm still eyes FDA approval - European Biotechnology Magazine
Transcript : IO Biotech, Inc.Special Call - MarketScreener
Cancer vaccine’s ‘narrow’ phase 3 fail won’t stop IO heading to FDA - Fierce Biotech
Danish cancer vaccine just misses the mark in phase 3 trial - medwatch.com
Pharma Boom: What’s Up With IO Biotech? - timothysykes.com
IO Biotech's Cylembio: A Game-Changing Cancer Vaccine with Strong Clinical Signal and Regulatory Pathway Potential - AInvest
IO Biotech stock rises as cancer vaccine shows promising results By Investing.com - Investing.com Australia
IO Biotech stock rises as cancer vaccine shows promising results - Investing.com
IO Biotech Shares Jump in Premarket on Positive Melanoma Treatment Trial Data - MarketScreener
Navigating the Crossroads: IO Biotech's Cylembio and the Regulatory Hurdles of a Novel Cancer Vaccine - AInvest
IO Biotech Reveals Phase 3 Trial Results for Cylembio - TipRanks
IO Biotech stock jumps on data for cancer shot (IOBT:NASDAQ) - Seeking Alpha
IO Biotech's cancer vaccines shows improvement in late-stage study goal - MarketScreener
IO Biotech’s melanoma treatment shows improved survival rates - Investing.com India
Finanzdaten der Io Biotech Inc-Aktie (IOBT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):